# Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03190278** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cellectis S.A.** · enrollment: 29 (actual)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** UCART123v1.2

## Key facts

- **NCT ID:** NCT03190278
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-19
- **Primary completion:** 2024-12-24
- **Final completion:** 2025-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190278, "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03190278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*